REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > O-glycoside > > Nitrogen Containing Hetero Ring > Polynucleotide (e.g., Rna, Dna, Etc.) Polynucleotide (e.g., Rna, Dna, Etc.)Polynucleotide (e.g., Rna, Dna, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027103 - Methods and compositions for silencing genes without inducing toxicity The present invention provides methods of post-transcriptional gene silencing which involve the use of a first dsRNA having substantial sequence identity to a target nucleic acid and a short, second dsRNA which inhibits dsRNA-mediated toxicity. These methods can be used to prevent or treat a disease or infection by silencing ... 02/01/07 - 20070027102 - Methods and compositions for treating macular degeneration This invention relates to methods of treating age-related macular degeneration (AMD). In particular, this invention provides methods of treating all forms of wet, age-related macular degeneration. The method of the invention is directed to the administration of an anti-vascular endothelial growth factor (anti-VEGF) compound to treat wet AMD. ... 02/01/07 - 20070027101 - Methods for treating ocular neovascular diseases Disclosed herein are methods for treating ocular neovascular disease using anti-VEGF therapy in combination with a second therapy that inhibits the development of ocular neovascularization or destroys abnormal blood vessels in the eye, such as photodynamic therapy. ... 02/01/07 - 20070027100 - Use of placental growth factor for preventing or treating ischemic diseases or stroke The present invention relates to prevention and treatment of strokes and ischemic diseases and to post-ischemic therapeutic treatment. The invention furthermore relates to the use of a growth factor or nucleic acids ensuring increased expression of a growth factor for treating, more particularly restoring the function of ischemic tissue, in ... 02/01/07 - 20070027099 - Gene therapy of hbv infection via adeno-associated viral vector mediated long term expression of small hairpin rna (shrna) The invention provides a vector comprising an AAV-shRNA vector. The vector is preferably rAAV-151i/1694i. The invention also provides a method of suppressing or inhibiting HBV replication in liver cells infected therewith, comprising administering an amount of an AAVB-shRNA vector effective to suppress, inhibit or reduce HBV replication. ... 02/01/07 - 20070027098 - Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof The invention relates to immunostimulatory oligonucleotide compositions. These oligonucleotides comprise an immunostimulatory octanucleotide sequence. These oligonucleotides can be administered in conjunction with an immunostimulatory peptide or antigen. Methods for modulating an immune response upon administration of the oligonucleotide are also disclosed. In addition, an in vitro screening method to identify ... 02/01/07 - 20070027097 - Small interfering rna with improved activity Chemically modified small interfering RNAs are described. Combinations of 2′-hydroxyl substitutions on the nucleotide riboses are shown to increase the longevity and extent of target gene knockdown in mammalian cells. ... 02/01/07 - 20070027096 - Aptamers to human epidermal growth factor receptor-3 The disclosure provided herein provides compositions of nucleic acid aptamers that bind human epidermal growth factor receptor-3 and methods for their use. ... 01/25/07 - 20070021375 - Genetic modification of targeted regions of the cardiac conduction system Disclosed are compositions, methods and systems for preventing or treating cardiac dysfunction, particularly cardiac pacing dysfunction by genetic modification of cells of targeted regions of the cardiac conduction system. In particular, a bio-pacemaker composition is delivered to cardiac cells to increase the intrinsic pacemaking rate of the cells, wherein the ... 01/25/07 - 20070021374 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting ... 01/25/07 - 20070021373 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting ... 01/25/07 - 20070021372 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting ... 01/25/07 - 20070021371 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting ... 01/25/07 - 20070021370 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting ... 01/25/07 - 20070021369 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting ... 01/25/07 - 20070021368 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting ... 01/25/07 - 20070021367 - Modulation of socs-3 expression Compounds, compositions and methods are provided for modulating the expression of SOCS-3. The compositions comprise oligonucleotides, targeted to nucleic acid encoding SOCS-3. Methods of using these compounds for modulation of SOCS-3 expression and for diagnosis and treatment of disease associated with expression of SOCS-3 are provided. ... 01/25/07 - 20070021366 - Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use Provided herein is a crystallized ternary structure of aldose reductase (AR) bound to NADPH and γ-glutamyl-S-(1,2-dicarboxyethyl)cysteinylglycine (DCEG). Also provided are specific inhibitors of glutathione-aldehyde binding to aldose reductase which are designed via at least computer modeling of the ternary AR:NADPH:DCEG structure and methods of designing and of screening the inhibitors ... 01/25/07 - 20070021365 - Inhibition of lysyl oxidase for treating tumor growth and diagnostics relating thereto Disclosed are methods of identifying lysyl oxidase inhibitors and the use of such inhibitors to prevent and treat tumors, particularly metastatic tumors, alone and in combination with chemotherapeutic agents. Further disclosed is the use of lysyl oxidase levels for measuring metastatic potential and survival. ... 01/25/07 - 20070021364 - Methods for genetic immunization The present invention relates to methods for delivering a genetic immunogen, comprising a nucleic acid capable of expressing an antigen, optionally complexed with a polymer. The nucleic acid is delivered to the host via hydrodynamic intravascular injection resulting in expression of an encoded antigen in extravascular cells and induction of ... 01/25/07 - 20070021363 - Genomic replacement therapy Genomic Replacement Therapy uses the human genome found in mantle dentin of a patient's tooth to affect other cells of the body. Mantle Dentin cells in the developed tooth do not reproduce, therefore the DNA is “younger”. Replacing the genome with a “younger” one will hopefully create beneficial effect to ... 01/25/07 - 20070021362 - Antisense antibacterial method and compound A method and antisense compound for inhibiting the growth of pathogenic bacterial cells are disclosed. The compound contains no more than 12 nucleotide bases and has a targeting nucleic acid sequence of no fewer than 10 bases in length that is complementary to a target sequence containing or within 10 ... 01/25/07 - 20070021361 - Methods and materials for modulating trpm2 The invention relates to antisense oligonucleotides, compositions and methods useful for modulating the expression of TRPM2. The compositions comprise antisense oligonucleotides, particularly antisense oligonucleotides targeted to nucleic acids encoding TRPM2. ... 01/25/07 - 20070021360 - Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase A pharmaceutical composition and formulations comprise preventative, prophylactic or therapeutic amounts of an oligo(s) anti-sense to a specific gene(s) or its corresponding mRNA(s), and a glucocorticoid and/or non-glucocorticoid steroid or a ubiquinone or their salts. The agents, composition and formulations are used for treatment of ailments associated with impaired respiration, ... 01/18/07 - 20070015724 - Prefoldin 4 in the treatment and diagnosis of cancer This invention provides methods employing prefoldin-4 (PFDN-4) nucleic acid and polypeptide sequences to detect cancer or a propensity to develop cancer, to monitor the efficacy of a cancer treatment, and/or for prognostic applications. Further, the invention provides methods of identifying inhibitors of PfDN-4 and methods of treating cancer by inhibiting ... 01/18/07 - 20070015723 - Antiviral oligonucleotides having a conserved g4 core sequence Modified oligonucleotides having a conserved G4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus or phospholipase A2 or to modulate the telomere length of a chromosome are provided. G4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnostics and therapeutics for ... 01/18/07 - 20070015722 - Double stranded compositions comprising a 3'-endo modified strand for use in gene modulation The present invention provides double stranded compositions that have a region that is complementary to a target nucleic acid. One of the targeting strand or the second strand comprises linked ribofuranosyl nucleosides and the other strand comprises linked modified nucleosides that have 3′-endo conformational geometry. The strands can be linked ... 01/18/07 - 20070015721 - Hiv-gag codon-optimised dna vaccines The invention provides a nucleotide sequence that encodes an HIV-1 gag protein or fragment thereof containing a gag epitope and a second HIV antigen or a fragment encoding an epitope of said second HIV antigen, operably linked to a heterologous promoter. Preferred polynucleotide sequences further encodes nef or a fragment ... 01/11/07 - 20070010474 - Nf-kappab oligonucleotide decoy molecules The present invention concerns double-stranded NF-κB decoy oligodeoxynucleotide (NF-κB dsODN) molecules that contain a core sequence capable of specific binding to an NF-κB transcription factor. In a particular aspect, the invention concerns NF-κB decoy molecules that preferentially bind p50/p65 and/or cRel/p50 heterodimers over p50/p50 homodimers. In another aspect, the invention ... 01/11/07 - 20070010473 - Nucleic acid ligands to integrins Methods are described for the isolation of nucleic acid ligands to integrins using the SELEX process. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the present invention are useful as therapeutic and diagnostic agents. ... 01/11/07 - 20070010472 - Oligonucleotide compositions and their use to induce differentiation of cells The present invention provides compositions comprising a 3′-OH, 5′-OH, chemically unmodified, synthetic phosphodiester nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and a pharmaceutically acceptable carrier, wherein the compositions are useful to induce ... 01/11/07 - 20070010471 - Hiv dna vaccine A DNA vaccines or immunogenic composition for providing an immune response against HIV without exhibiting pathogenicity in the immunized individual because of the disruption of the ability of the DNA molecules to encode for viral proteins critical in producing pathogenicity. The DNA molecule is derived by passaging a SHIV in ... 01/11/07 - 20070010470 - Immunomodulatory oligonucleotides Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides ... 01/11/07 - 20070010469 - Gene products differentially expressed in cancerous cells iii The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of cancer cells. These methods are useful for treating cancer. ... 01/11/07 - 20070010468 - Methods and compositions for the inhibition of stat5 in prostate cancer cells The present invention relates to compositions and methods for the treatment of prostate cancer. In certain embodiments, the invention relates to compositions and methods for the inhibition of prostate cancer cell growth, comprising inhibiting the activity of Stat5 in prostate cancer cells. ... 01/11/07 - 20070010467 - Targeted double stranded rna mediated cell killing A method of killing a specific target cell/tissue is disclosed. The method comprises exposing the specific target cell/tissue to a composition-of-matter comprising a double stranded RNA molecule associated with a targeting moiety selected capable of targeting to the specific target cell/tissue, thereby killing the specific target cell/tissue. ... 01/04/07 - 20070004668 - Antisense permeation enhancers A pharmaceutical composition comprising an antisense oligonucleotide and a permeation enhancer that comprises a multi-carbon backbone having a functional group and also one or more side chains which have one or more carbon atoms and, optionally, one or more functional groups. ... 01/04/07 - 20070004667 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA ... 01/04/07 - 20070004666 - Methods for modulating apoptotic cell death Proteinaceous transcription factors that regulate the transcription of genes and/or the translation of messenger RNA encoding proteins involved in apoptosis, such as CD95 and p53, are disclosed, together with methods for the use of such transcription factors in the modulation of apoptotic cell death. Methods for regulating apoptosis have therapeutic ... 01/04/07 - 20070004665 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA ... 01/04/07 - 20070004664 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA ... 01/04/07 - 20070004663 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA ... 01/04/07 - 20070004662 - Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma The present invention provides a method of treating cancer by providing to a subject in need thereof an immunogenic composition comprising a nucleic acid construct encoding a polypeptide comprising CTL epitopes PSMA288-297 and PRAME425-433, or a cross-reactive analogue. In embodiments of the present invention there is provided methods and compositions ... 01/04/07 - 20070004661 - Antisense antiviral compound and method for treating influenza viral infection The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal. The antisense antiviral compounds ... 01/04/07 - 20070004660 - Synergistic modulation of flt3 kinase using alkylquinolines and alkylquinazolines where R1, R2, R3, Z, G, Q and X are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3. ... 01/04/07 - 20070004659 - Method for preventing or delaying the onset of diabetes A method for preventing, delaying the onset of or treating diabetes in a patient comprising selecting a patient who is susceptible to developing diabetes, who is developing diabetes or who is diabetic and administering to the patient one or more than one dose of a pharmaceutical agent comprising a polynucleotide ... 01/04/07 - 20070004658 - Method and means for treatment of osteoarthritis The present invention relates to in vivo and in vitro methods, agents and compound screening assays for inducing anabolic stimulation of chondrocytes, including cartilage formation enhancing pharmaceutical compositions, and the use thereof in treating and/or preventing a disease involving a systemic or local decrease in mean cartilage thickness in a ... 01/04/07 - 20070004657 - Diagnosis and treatment of kidney fibrosis and other fibrotic diseases The present invention provides methods of treatment of fibrosis by identification and isolation of polynucleotide sequences, the expression of which is altered in fibrosis. The present invention also relates to the use of these isolated polynucleotides and the polypeptides encoded thereby as probes for diagnosis, for screening of treatment modalities ... 01/04/07 - 20070004656 - Trans-sialidases obtained from trypanosoma congolense The invention relates to novel enzymes, which transfer sialic acid from a donor molecule onto an acceptor molecule (trans-sialidases). The enzymes are isolated from the protozoan Trypanosoma congolense. The invention also relates to functional equivalents of said enzymes, to the nucleic acid sequences and amino acid sequences that code for ... 01/04/07 - 20070004655 - Nr-cam gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors The present invention relates to the identification of a novel role of Nr-CAM in cell transformation and aberrant cellular proliferation. In particular, the present invention relates to the altered gene expression of Nr-CAM in a number of primary tumors and cell lines derived from tumors, in addition to, the altered ... 12/28/06 - 20060293272 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA ... 12/28/06 - 20060293271 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA ... 12/28/06 - 20060293270 - Methods and compositions for treating ocular disorders This invention relates to methods of treating ocular disease. The method of the invention is directed to the administration of an anti-vascular endothelial growth factor (anti-VEGF) compound to treat such disease. ... 12/28/06 - 20060293269 - Antisense modulation of superoxide dismutase 1, soluble expression Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of ... 12/28/06 - 20060293268 - Antisense antiviral compounds and methods for treating foot and mouth disease An antiviral antisense composition and method for treating foot-and-mouth disease virus (FMDV) in veterinary animals is disclosed. The composition contains an antisense compound that has a sequence effective to target at least 12 contiguous bases of an FMDV RNA sequence within a region of the positive-strand genomic RNA defined by ... 12/28/06 - 20060293267 - Dual functional oligonucleotides for use as anti-viral agents The present invention is based, in part, on the discovery that endogenous mRNAs, such as viral miRNAs, can be recruited for translational repression of target mRNAs, such as viral target mRNAs. The RNA-silencing agents and the methods described herein, thereby provide a means of treating viral infections, of treating diseases ... 12/28/06 - 20060293266 - Phosphodiesterase 4d in the ryanodine receptor complex protects against heart failure The present invention provides compositions useful for treating and preventing ryanodine receptor associated disorders comprising a PDE-associated agent and a pharmaceutically acceptable carrier. The present invention also provides methods for treating or preventing ryanodine receptor associated disorders including cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and ... 12/28/06 - 20060293265 - Methods involving aldose reductase inhibitors Embodiments of the invention include methods and compositions involving aldose reductase inhibitors for the treatment of sepsis and autoimmune diseases, including Type I diabetes and rheumatoid arthritis. The invention also pertains to preventing the loss of cardiac muscle contractibility. ... 12/28/06 - 20060293264 - Stat3 decoy oligonucleotides and uses therefor A composition is provided that is useful in treating cancers in which STAT3 is activated, such as squamous cell carcinomas including squamous cell carcinoma of the head and neck. The composition comprises an effective amount of a STAT3 decoy and a pharmaceutically acceptable carrier. Also provided are methods of treating ... 12/28/06 - 20060293263 - Preparation for preventing contact of pathogenic matter with living organism Intermolecular mutual recognition between pathogenic matter, such as allergen group or disease-causing microbe, capable of functioning at the attachment thereof to living organism and a living organism is inhibited by the use of pectins or nucleic acids. ... 12/28/06 - 20060293262 - Inhibition of gene expression using rna interfering agents The present invention is based, at least in part, on the discovery of compositions and methods for the treatment and prevention of infectious diseases or disorders, e.g., HIV infection, AIDS, and AIDS-related diseases. In particular, the present invention pertains to methods of modulating cellular gene expression or protein activity, e.g., ... 12/21/06 - 20060287274 - Phosphoepoxides, method for making same and uses Cat+ is an organic or inorganic cation, n is an integer between 2 and 20, processes for the production thereof and uses thereof, in particular therapeutic uses and for activating primate Tγ9δ2 lymphocytes. ... 12/21/06 - 20060287273 - Methods and reagents for inhibiting cell proliferation Methods and reagents for reducing expression of proteins involved in intracellular signalling are disclosed. Specifically, siRNA sequences are provided for reducing expression of Src, stat3, and c-myc gene products. Combination treatments are disclosed for inhibiting cell proliferative pathways, and for reducing tumor growth in breast and colon cancer. ... 12/21/06 - 20060287272 - Methods for determining specificity of rna silencing and for genetic analysis of the silenced gene or protein Methods and kits for determining the specificity of siRNAs for their targets are provided. Also provided is a method for performing genetic analysis of the target protein or gene using different versions of a synthetic gene to complement the phenotype induced by RNAi-mediated silencing of the target protein and/or gene ... 12/21/06 - 20060287271 - Dinucleoside poly(borano)phosphate derivatives and uses thereof Dinucleoside poly(borano)phosphates are provided that can be useful for prevention or treatment of diseases or disorders modulated by P2Y receptors such as type 2 diabetes, cystic fibtosis and cancer. ... 12/21/06 - 20060287270 - Methods of using redox-active surfactants to control polymer interactions The present invention provides methods utilizing redox-active surfactants to provide electrochemical control over polymer interactions. In one embodiment, the invention is directed to a transfection method using a redox-active transfection agent that preferentially promotes transfection dependent on the oxidation state of the transfection agent. Accordingly, certain methods according to the ... 12/21/06 - 20060287269 - Short interfering nucleic acid hybrids and methods thereof Disclosed herein are siHybrids used for gene silencing. An siHybrid is a short double-stranded molecule comprised of one strand of DNA and one strand of RNA, annealed together, with a 2-base overhang at each 3′ end. In addition to DNA and RNA, it may contain PNA or other nucleic acid ... 12/21/06 - 20060287268 - Splice-region antisense composition and method Antisense compositions targeted against an mRNA sequence coding for a selected protein, at a region having its 5′ end from 1 to about 25 base pairs downstream of a normal splice acceptor junction in the preprocessed mRNA, are disclosed. The antisense compound is RNase-inactive, and is a phosphorodiamidate-linked morpholino oligonucleotide ... 12/21/06 - 20060287267 - Rna interference mediated inhibition of respiratory syncytial virus (rsv) expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating sespiratory syncytial virus (RSV) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of RSV gene expression ... 12/21/06 - 20060287266 - Rna interference mediated ihibition of gene expression using chemically modified short interfering nucleic acid (sina) The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA ... 12/21/06 - 20060287265 - Apoptosis-specific eif-5a and polynucleotides encoding same The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5-A1, nucleic acids and polypeptides and methods for increasing or decreasing expression of apoptosis-specific eIF-5A. The invention also relates to methods of increasing or decreasing apoptosis. ... 12/21/06 - 20060287264 - Rnai modulation of the bcr-abl fusion gene and uses thereof The invention relates to compositions and methods for modulating the expression of Bcr-Abl, and more particularly to the down-regulation of Bcr-Abl mRNA and Bcr-Abl protein levels by oligonucleotides via RNA interference, e.g., chemically modified oligonucleotides. ... 12/21/06 - 20060287263 - Methods and compositions for inducing antigen-specific immune responses Vaccine compositions comprising (a) an oligonucleotide, (b) and immune stimulating complex and (c) an antigen induce a strong interferon-gamma immune response. Both oligonucleotides containing immune stimulatory motifs and oligonucleotides lacking immune stimulatory motifs contribute to an interferon-gamma response when administered with an immune stimulating complex. ... 12/21/06 - 20060287262 - Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked ... 12/21/06 - 20060287261 - Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and an immunostimulatory oligonucleotides of ... 12/21/06 - 20060287260 - Oligonucleotides comprising a non-phosphate backbone linkage One aspect of the present invention relates to a ribonucleoside substituted with a phosphonamidite group at the 3′-position. In certain embodiments, the phosphonamidite is an alkyl phosphonamidite. Another aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, ... 12/21/06 - 20060287259 - Compositions and methods for combined therapy of disease A desired physiological state can be induced by altering the amount of gene products in target cells of a subject. The target cells are treated with at least one compound designed to reduce expression of at least one first gene by RNAi, and with at least one compound designed to ... 12/21/06 - 20060287258 - Treatment of menorrhagia, dysmenorrhoea or endometriosis A method of combating menorrhagia, dysmenorrhoea or endometriosis in a female individual, the method comprising administering to the individual at least one agent that that reduces the effect of prokineticin 1 on a prokineticin receptor. ... 12/14/06 - 20060281704 - Regulation of endogenous gene expression in cells using zinc finger proteins The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins. ... 12/14/06 - 20060281703 - Treatment of disease using an improved regulated expression system The present invention provides an improved, expression system for the regulated expression of an encoded protein or nucleic acid therapeutic molecule in the cells of a subject, for use in the treatment of disease. In particular, the present invention provides an improved, regulated gene expression system, and pharmaceutical compositions and ... 12/14/06 - 20060281702 - Combinatorial selection of phosphorothioate aptamers for rnases The present invention includes the selection and isolation of thioaptamers that target the ribonuclease domains of enzymes, e.g., HIV reverse transcriptase. ... 12/14/06 - 20060281701 - Antisense antiviral compounds and methods for treating a filovirus infection The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Filoviridae family, and in the treatment of a viral infection. The compounds and methods relate to the treatment of viral infections in mammals including primates by Ebola and Marburg ... 12/14/06 - 20060281700 - Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators where R3, B, Z, Q, p, q and R1 are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3. ... 12/14/06 - 20060281699 - Methods, compositions and compound assays for inhibiting amyloid-beta protein production A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a PROTEASE polypeptide, or fragment thereof, and measuring a compound-PROTEASE property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including cleaved protease substrate and/or amyloid ... 12/14/06 - 20060281698 - Modulation of apolipoprotein (a) expression Compounds, compositions and methods are provided for modulating the expression of apolipoprotein(a). The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein(a). Methods of using these compounds for modulation of apolipoprotein(a) expression and for diagnosis and treatment of disease associated with expression of apolipoprotein(a) are provided. ... 12/14/06 - 20060281697 - Methods and kits for diagnosing and treating b-cell chronic lymphocytic leukemia The present invention relates to methods and kits for detecting several polynucleotide sequence found to be indicative of a poor prognosis of B-CLL. All the polynucleotides are transcribed from a region on human chromosome 12p21-22. Most of the polynucleotides do not encode larger polypeptides, but may encode small peptides, they ... 12/14/06 - 20060281696 - Decoy-oligonucleotide-inhibition of cd40-expression The present invention relates to decoy oligonucleotides with the nucleic acid sequence according to SEQ ID NO: 1 to 36 and their use as pharmaceutical agents. ... 12/07/06 - 20060276427 - Regulation of endogenous gene expression in cells using zinc finger proteins The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins. ... 12/07/06 - 20060276426 - Human peroxisome proliferator activated receptor gamma (ppargamma) gene regulatory sequences and uses therefor This invention relates to the isolation and cloning of the promoter and other control regions of human PPARγ gene. It provides methods for identifying and screening for agents useful for the treatment of diseases and pathological conditions affected by the level of expression of the PPARγ gene. These agents interact ... 12/07/06 - 20060276425 - Antisense oligomers and methods for inducing immune tolerance and immunosuppression A method and composition for inducing human dendritic cells to a condition of reduced capacity for antigen-specific activation of T cells, and, in mature dendritic cells, increased production of extracellular IL-10 is disclosed. A population of dendritic cells is exposed to a substantially uncharged antisense compound, including partially positively charged, ... 12/07/06 - 20060276424 - Compositions and methods for treatment of prostate and other cancers Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for ... 12/07/06 - 20060276423 - Survivin-directed rna interference-compositions and methods The present invention is directed to compositions and methods for inhibiting the expression of survivin in cells expressing survivin. The invention is also directed to methods of treating conditions associated with elevated survivin, such as hyperproliferative disorders. More particularly, the invention is directed to inhibition of survivin expression using short ... 12/07/06 - 20060276422 - Rna interference mediated inhibition of b7-h1 gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating B7-H1 (also known as PD-L1) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of B7-H1 gene ... 12/07/06 - 20060276421 - Staple type oligonucleotide and drug comprising the same Conventional oligonucleotides are opened at both ends and thereby unstable. The stability of them against catabolic enzymes is increased by phosphorothioate modification, but such phosphorothioate causes toxicity. The present invention provides oligonucleotides and medicaments in which these problems are improved. That is, it provides a staple oligonucleotides and medicaments containing ... 12/07/06 - 20060276420 - Mesoderm and definitive endoderm cell populations The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy. ... 11/30/06 - 20060270624 - Gapped 2' modified oligonucleotides Oligonucleotides and other macromolecules are provided that have increased nuclease resistance, substituent groups for increasing binding affinity to complementary strand, and sub-sequences of 2′-deoxy-erythro-pentofuranosyl nucleotides that activate RNase H enzyme. Such oligonucleotides and macromolecules are useful for diagnostics and other research purposes, for modulating protein in organisms, and for the ... 11/30/06 - 20060270623 - Rna interference mediated treatment of polyglutamine (polyq) repeat expansion diseases using short interfering nucleic acid (sina) The present invention concerns compounds, compositions, and methods for the study, diagnosis, and treatment of diseases and conditions associated with polyglutamine repeat (polyQ) allelic variants that respond to the modulation of gene expression and/or activity. The present invention also concerns compounds, compositions, and methods relating to diseases and conditions associated ... 11/30/06 - 20060270622 - Article of manufacture and method for disease treatment A method of treating a disease associated with a pathological cell population is disclosed. The method comprises increasing an association of complement with the pathological cell population in a subject in need of treatment, and decreasing a level and/or activity of a polypeptide in the pathological cell population, the polypeptide ... 11/30/06 - 20060270621 - Inhibition of hair growth with rnai targeting desmoglein 4 and nude mrnas Methods for inhibition of desmoglein 4 and nude protein mRNA using RNA interference are described, in particular methods for inhibition or hair growth or hair removal. Also described are nucleic acid constructs for RNAi-mediated inhibition of desmoglein 4 and nude protein mRNA and compositions including such constructs. ... 11/30/06 - 20060270620 - Method of enhancing therapeutic effect of nucleic acids The present invention is a method of eliciting an antitumor effect in vivo comprising the steps of identifying a species representative of a treatment subject, identifying at least one non-coding nucleic acid sequence, introducing the at least one nucleic acid to at least one tumor in the treatment subject and ... 11/30/06 - 20060270619 - Genes and polypeptides relating to human pancreatic cancers The present application provides novel human genes C1958V1 or C1958V2 whose expression is markedly elevated in pancreatic cancers compared to corresponding non-cancerous tissues. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of pancreatic cancer, and as target molecules for developing drugs against ... 11/30/06 - 20060270618 - Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases The present invention relates to a novel pharmaceutical composition comprising interferon-γ or pirfenidone and a diagnostic array of candidate polynucleotides for the improved treatment of lung diseases, especially for all forms of interstitial lung diseases. This invention describes the combination of molecular diagnosis and clinical therapy as a novel medication ... 11/23/06 - 20060264396 - Composition for treatment of prevention of endometrial cancer and method of preventing or treating endometrial cancer using the composition Provided are a composition for the treatment or prevention of an endometrial cancer including a nuclear acid molecule inducing RNA interference against human syndecan-1 gene expression and a pharmaceutically acceptable carrier, and a method of treating or preventing an endometrial cancer including administering the composition to an individual. ... 11/23/06 - 20060264395 - Modulation of apolipoprotein c-iii expression Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein C-III. Methods of using these compounds for modulation of apolipoprotein C-III expression and for diagnosis and treatment of disease associated with expression of apolipoprotein C-III are provided. ... 11/23/06 - 20060264394 - Livin-specific sirnas for the treatment of therapy-resistant tumors Provided is the use of siRNAs which are specific for the inhibitor of apoptosis protein (IAP) livin to sensitize tumor cells for apoptosis by down-regulating livin expression. ... 11/23/06 - 20060264393 - Methods for evaluating genetic susceptibility and therapy for chronic inflammatory diseases The invention discloses a knockout mouse that is homozygous for a RUNX3 null allele, as a novel model for chronic inflammatory disease. The present invention provides methods for treating T cell-related inflammatory conditions by cell therapy, gene therapy or antisense for up regulating or down regulating RUNX3. The invention further ... 11/23/06 - 20060264392 - Modulators of angiogenesis The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding “angiogenesis regulatory proteins and nucleic acids” which are involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic ... 11/23/06 - 20060264391 - Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences The invention provides new methods of preventing and/or treating herpes virus infections, particularly reducing infection, one or more symptoms and recurrence of one or more symptoms of herpes simplex virus infection. A polynucleotide comprising an immunostimulatory sequence (an “ISS”) is administered to an individual which is at risk of being ... 11/16/06 - 20060258611 - Inhibition of sars-associated coronavirus (scov) infection and replication by rna interference The present invention relates to therapeutic agents useful for the treatment of Severe Acute Respiratory Syndrome (SARS) in humans. In particular, the present invention relates to RNA interference (RNAi) molecules useful for inhibiting the infection and replication of hSARS virus. Preferably, the RNAi molecules target the replicase region of the ... 11/16/06 - 20060258610 - Modulation of stat 6 expression for the treatment of airway hyperresponsiveness Disclosed herein are compounds, compositions and methods for modulating the expression of STAT 6 in a cell, tissue, or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of STAT 6, airway hyperresponsiveness, and/or ... 11/16/06 - 20060258609 - Method for inhibition of lipogenesis by regulating prp19 expression The downregulation of PRP 19 (precursor RNA processing 19) protein expression results in effectively reducing the expression of SCD1 (stearyl CoA desaturase-1), the key lipogenic enzyme, and its down-stream triacylglycerol synthesis enzymes, DGAT-1 (diacyglycerol acyltransferase-1) and GPAT (glycerol-phosphate acyltransferase), as well as the intracellular content of neutral lipids, the major ... 11/16/06 - 20060258608 - Rnai modulation of rsv and therapeutic uses thereof The present invention is based on the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based ... 11/16/06 - 20060258607 - Ghrelin binding nucleic acids The present invention is related to a nucleic acid, preferably binding to ghrelin, whereby the nucleic acid comprises a first stretch Box A, and a second stretch Box B, whereby the first stretch Box A comprises about 25 consecutive nucleotides, the second stretch Box B comprises about six to eight ... 11/16/06 - 20060258606 - Transforming growth factor-beta response element decoys and methods Products and methods for treating fibrosis, liver cirrhosis and cancer, and for altering or modulating the expression of genes regulated by transforming growth factor—beta (TGF-β) are provided. Nucleic acid molecules comprising TGF-response elements have a high affinity for transcription factors modulated by TGF-β. In one embodiment, nucleic acid molecules comprising ... 11/16/06 - 20060258605 - Nucleolin-mediated cancer diagnostics and therapy The present invention provides for diagnostic kits for identifying cancer patients who are more susceptible to cancer therapies employing endostatin and other angiogenesis inhibitors, based upon the discovery that Nucleolin is a specific receptor for Endostatin. In particular, the diagnostic kits include antibody molecules against Nucleolin, DNA or RNA molecules ... 11/16/06 - 20060258604 - Compositions and methods for the treatment of inflammatory bowel disease utilizing nf-kappab decoy polynucleotides Provided herein is a method of treating or preventing inflammatory bowel disease (IBD) in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising an NF-κB decoy polynucleotide. ... 11/16/06 - 20060258603 - Transposon-based targeting system The present invention relates to a targeting system comprising, preferably as distinct components (a) a transposon which is devoid of polynucleotide encoding a functional transposase comprising (aa) a polynucleotide of interest and; (ab) a DNA sequence specifically recognized by a DNA binding domain; and (ba) a fusion protein comprising (i) ... 11/16/06 - 20060258602 - Site-specific gene conversion promoter and gene therapeutic It is intended to provide a preparation whereby an oligonucleotide is efficiently transferred into a cell and the localization thereof in nucleus is promoted, a preparation for facilitating the conversion of the base sequence of a target genomic gene, and a preparation for gene therapy. Namely, a preparation for facilitating ... 11/16/06 - 20060258601 - Formulation for inwardly transferring nucleic acids into eucaryotic cells The present invention relates to a pharmaceutical formulation for the funnelling of nucleic acids into eukaryotic cells, characterised in that the formulation has a pH-value within the range of pH 6.0 to pH 7.4, and/or an anion concentration within the range from 5 to 100 mmol/l and/or provides nonsteroidal anti-inflammatory ... 11/09/06 - 20060252724 - Method and composition for modulating bone growth Methods and compositions are provided for the treatment of defects and disease involving osteoporosis or osteopenic conditions. The methods comprise applying to the site of osteoporotic or osteopenic conditions a composition comprising a BMP-3 inhibitor or antagonist. The invention further provides methods and compositions for modulating or regulating the formation ... 11/09/06 - 20060252723 - Combined therapy utilizing reduction of dna methyltransferase expression and/or activity and interferon The invention provides methods for the treatment of cancer comprising a reduction of DNA methyltransferase expression and/or activity and treatment and/or induction of interferon. The invention overcomes resistance of cancer cells to interferon ... 11/09/06 - 20060252722 - Oligomeric compounds and compositions for use in modulation of pri-mirnas Compounds, compositions and methods are provided for modulating the levels expression, processing and function of pri-miRNAs. In particular, methods and compounds are provided for the modulation of the levels, expression, processing or function of polycistronic pri-miRNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs and pri-miRNAs. Further provided ... 11/09/06 - 20060252721 - Potent lna oligonucleotides for the inhibition of hif-1a expression The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5′-(Tx)GxGxcsasasgscsastscscsTxGxT-3′ and 5′-(Gx)TxTxascstsgscscststscsTxTxA-3′, wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-D-oxy-LNA nucleotide analogue or a 2-deoxynucleotide, subscript “s” designates a phosphorothioate link ... 11/09/06 - 20060252720 - Modulation of hif1 beta expression Compounds, compositions and methods are provided for modulating the expression of HIF1-beta. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1-beta. Methods of using these compounds for modulation of HIF1-beta expression and for diagnosis and treatment of diseases and conditions associated with expression of HIF1-beta are provided. ... 11/09/06 - 20060252719 - Compositions and methods to modulate h. influenzae pathogenesis The present invention discloses novel signaling pathways controlling the pathogenesis of the human respiratory bacterium, Haemophilus influenzae. The lipooligosaccharide-phosphorylycholine (LOS-PC) cell surface epitope of H. influenzae enhances pathogenesis but also increases bacterial susceptibility to innate and adaptive immunity and the administration of therapeutic compounds. Modulation of the LOS-PC epitope may ... 11/09/06 - 20060252718 - Sphingolipids polyalkylamine conjugates for use in transfection The present invention concerns the use of a sphingoid-polyalkylamine conjugate comprising a sphingoid backbone carrying, via a carbamoyl bond, at least one polyalkylamine chains as a capturing agent of nucleic acid molecules. The present invention also provides the use of the sphingoid polyalkylamine conjugate for the preparation of a pharmaceutical ... 11/09/06 - 20060252717 - Sphingoid polyalkylamine conjugates for vaccination The present invention concerns the use of a sphingoid-polyalkylamine conjugate as a capturing agent of biologically active molecules, such as antigens. In a particular embodiment, the spinogid-polyalkylamines are used for the preparation of pharmaceutical composition for modulating the immune response of a subject. Other aspects of the invention concern methods ... 11/09/06 - 20060252716 - Method for reversing the immunosuppressive effects of the melanoma inhibitory activity mia A method for stimulating immune cells and/or the immune system, and/or reducing invasion and/or metastasis of tumor cells by inhibiting expression and/or functional activity of “Melanoma Inhibitory Activity” MIA. ... 11/02/06 - 20060247202 - Recombinant constructs and their use in reducing gene expression Recombinant constructs useful for reducing the expression of endogenous mRNA and any substantially similar endogenous mRNA are disclosed. In particular, a recombinant construct comprising, inter alia, a suitable nucleic acid sequence and its reverse complement can be used to alter the expression of any homologous, endogenous RNA (i.e., the target ... 11/02/06 - 20060247201 - Myeloid colony stimulating factor and uses thereof The identification of the HYAL1 hyaluronidase enzyme as a human plasma-derived myeloid colony-stimulating factor (CSF), herein designated CSF5-hyaluronidase, its recombinant production and methods of use are described. This protein may be used for the treatment of myelosuppression as may occur after irradiation, chemotherapy or other diseases where an increase in ... 11/02/06 - 20060247200 - Methods and uses of leukotriene b4 hydroxylases to treat diseases Methods and uses are described for treating or preventing diseases of humans or non-human animals by reducing the amount of active leukotriene B4 (LTB4) in those in need of such treatment using LTB4 hydroxylases. In certain embodiments, LTB4 hydroxylase is administered in combination with nicotinamide adenine dinucleotide phosphate and/or an ... 11/02/06 - 20060247199 - Methods and products for manipulating uncoupling protein expression The invention is based in part on the discovery that uncoupling proteins (UCPs) are expressed in the plasma membrane of rapidly dividing cells but not of growth arrested, chemotherapy resistant cells. It has also been found according to the invention that UCP is expressed in the lysosomal membrane under certain ... 11/02/06 - 20060247198 - Tgf-beta type receptor cdnas encoded products and uses therefor DNA encoding TGF-β type III receptor of mammalian origin, DNA encoding TGF-β type II receptor of mammalian origin, TGF-β type III receptor, TGF-β type II receptor and uses therefor. ... 11/02/06 - 20060247197 - Method for down-regulating gene expression in fungi The present invention concerns methods for controlling fungus infestation via dsRNA mediated gene silencing, whereby the intact fungus cell(s) are contacted with a double-stranded RNA from outside the fungal cell(s) and whereby the double-stranded RNA is taken up by the intact fungal cell(s). In one particular embodiment, the methods of ... 11/02/06 - 20060247196 - Yeast genes that affect viral replication An antiviral agent comprising an altered MAB1, MAB2, MAB3, or OLE1i gene, gene homologs or related genes is disclosed. In another embodiment, the present invention is a method of creating a virus resistant organism comprising creating a transgenic organism comprising an antiviral agent selected from the group of altered MAB1 ... 11/02/06 - 20060247195 - Method of altering cell properties by administering rna The invention relates to the alteration of cell properties using RNA molecules. In particular, it relates to the alteration of the ability of cells to mobilise, migrate, integrate, proliferate and/or differentiate. For example, it relates to the induction of differentiation of stem cells, including the acquisition of the ability to ... 11/02/06 - 20060247194 - Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating beta-secretase (BACE), amyloid precurson protein (APP), PIN-1, presenillin 1 (PS-1) and/or presenillin 2 (PS-2) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity ... 11/02/06 - 20060247193 - Regulation of gene expression by dna interference The present invention provides products and methods for modulating expression of a target gene in a cell. One such method includes introducing into the cell a polynucleotide that forms a duplex region with an mRNA transcribed from said target gene, where the duplex region comprises a mammalian miRNA target region. ... 11/02/06 - 20060247192 - Control of apoptosis A method for suppressing the expression of a selected apoptosis-related gene in a cell the method comprising introducing into the cell a molecule comprising (1) a nucleic acid binding portion which binds to a site at or associated with the selected gene which site is present in a genome and ... 11/02/06 - 20060247191 - Chimeric cytoplasmic signalling molecules Nucleic acids are described which code for chimeric cytoplasmic signalling molecules containing at least one cytoplasmic signalling sequence derived from CD134 or ICOS. The nucleic acids may be expressed in cells to produce chimeric receptors and other proteins which are able to regulate cell activation processes. Such regulated cells are ... 11/02/06 - 20060247190 - Compositions and methods for treating human papillomavirus mediated disease The invention includes methods of treating an HPV-mediated disease by administration to an individual of a pharmaceutical composition comprising a nucleic acid that encodes a polypeptide comprising an epitope of a naturally occurring HPV protein. The methods include the selection of individuals for treatment with the composition according to the ... 10/26/06 - 20060241076 - Modified oligoribonucleotide analogs with enhanced immunostimulatory activity The invention provides immunostimulatory compositions and methods for their use. In particular, the immunostimulatory compositions of the invention include RNA-like polymers that incorporate an immunostimulatory sequence motif and at least one chemical modification to confer improved stability against nuclease degradation and improved activity. Specific modifications involving phosphate linkages, nucleotide analogs, ... 10/26/06 - 20060241075 - Rna interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating Desmoglein (e.g, DSG1, DSG2, DSG3, and/or DSG4) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of ... 10/26/06 - 20060241074 - Methods for treatment of pain The present invention relates to a method for the treatment or prevention of pain by administering to an animal an agent that decreases the activity of the complement cascade. ... 10/26/06 - 20060241073 - Means and methods for counteracting fatty acid accumulation The invention provides a method for, at least, in part, counteracting a disease involving accumulation of a fatty acid, the method comprising administering a compound which is capable of inducing and/or upregulating omega-oxidation of the fatty acid, or whose metabolite is capable of inducing and/or upregulating omega-oxidation of the fatty ... 10/26/06 - 20060241072 - Oligomeric compounds for use in gene modulation The present invention provides modified oligomeric compounds and compositions of oligomeric compounds for use in the RNA interference pathway of gene modulation. The modified oligomeric compounds include siRNA and asRNA having at least one affinity modification. The present invention also provides methods for modulating gene expression using the modified oligomeric ... 10/26/06 - 20060241071 - Functional synthetic molecules and macromolecules for gene delivery The present invention describes a synthetic non-viral vector composition for gene therapy and the use of such compositions for in vitro, ex vivo and/or in vivo transfer of genetic material. The invention proposes a pharmaceutical composition containing 1) a non-cationic amphiphilic molecule or macromolecule and its use for delivery of ... 10/26/06 - 20060241070 - Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treament of cancer The present invention provides antisense oligonucleotides directed to a mammalian ribonucleotide reductase R2 gene and combinations of the antisense oligonucleotides with one or more chemotherapeutic agents for use in the treatment of cancer. ... 10/26/06 - 20060241069 - Treatment of hyperproliferative disease A short interfering RNA (siRNA) duplex that includes complementary sense and anti-sense sequences corresponding to at least part of the A3 adenosine receptor (A3AR) mRNA sequence, a double-stranded RNA (dsRNA) construct that can be converted within a cell into a siRNA duplex and a transcript system that can induce transcription ... 10/26/06 - 20060241068 - Novel actin-associated cytosekeltone protein lacs The present invention provides the novel actin-related cytoskeletal protein LACS and genes encoding the protein. ... 10/26/06 - 20060241067 - Methods for inhibiting angiogenesis, cell migration, cell adhesion, and cell survival The invention relates to methods for detecting and inhibiting angiogenesis, cell migration, cell adhesion, and/or cell survival in endothelial and non-endothelial cells as well as in normal and tumor cells. The invention further relates to methods for screening test compounds for their ability to inhibit angiogenesis, cell migration, cell adhesion, ... 10/26/06 - 20060241066 - Decoy composition for treating and preventing inflammatory disease It is intended to efficiently treat an inflammatory disease without causing side effects. This object can be achieved by providing a medicinal composition for treating and preventing an inflammatory disease and disorders, and disorders caused by the disease and disorders which contains at least one decoy of NF-κB or an ... 10/19/06 - 20060234973 - Transcription factor rna interference reagents and methods of use thereof The present invention concerns methods and reagents useful in modulating transcription factor gene expression in a variety of applications, including methods of use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering ... 10/19/06 - 20060234972 - Compositions and their uses directed to thymus and activation-regulated chemokine (tarc) Disclosed herein are compounds, compositions and methods for modulating the expression of TARC in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression ... 10/19/06 - 20060234971 - Calpains as targets for inhibition of prion propagation The present invention relates to methods for the inhibition of disease-associated prion formation and propagation. Such methods are based on inhibition of PrPSc cleavage, which prevents PrPSc accumulation and results in reduced prion titers. More particularly, the present invention relates to endoproteolytic cleavage of PrPSc by calpain, a calcium (Ca2+)-activated ... 10/19/06 - 20060234970 - Methods and compositions for the treatment of eye disorders with increased intraocular pressure The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of ... 10/19/06 - 20060234969 - Compositions and methods for inhibiting inflammation of vessel walls and formation of neointimal hyperplasia Compositions and methods for inhibiting inflammation of vessel wall and/or formation of neointimal hyperplasia by gene therapy using a soluble Flt-1 (sFlt-1) gene, are provided. VEGF has an essential role in the development of neointimal hyperplasia by causing inflammation. sFlt-1 gene transfer to the site of vascular injury blocks Flt-1-mediated ... 10/19/06 - 20060234968 - Inhibition of the cd95 ligand/receptor system for the treatment of neurological disorders and injuries The present invention relates to the use of inhibitors of the CD95 ligand/receptor system for the manufacture of a medicament for the treatment of neurological disorders or injuries in a mammal, particularly for the treatment of spinal cord injury, more particularly for the treatment of paraplegia. ... 10/19/06 - 20060234967 - Human protooncogene and protein encoded therein The present invention relates to a novel proto-oncogene HPP1 (Human proto-oncogene 1), which is non-homologous to existing oncogenes and the protein encoded by the said oncogene. This novel proto-oncogene can be advantageously used in diagnosing of various cancers; in construction of transformed animals; and in anti-sense gene therapy. The present ... 10/19/06 - 20060234966 - Method for expressing inducible rna [in cells, nucleic acid molecules therefor and cells transformed by said molecules A method of expressing RNAi in cells including introducing into cells a molecule of nucleic acid including the sequence sense and antisense of RNAi placed under the control of a promoter of single transcription, which sense and antisense sequences are separated by a sequence of DNA including a sequence for ... 10/19/06 - 20060234965 - Novel full-length genomic rna of japanese encephalitis virus, infectious jev cdna therefrom, and use thereof The present invention relates to a novel genomic RNA of Japanese encephalitis virus (JEV) and an infectious JEV cDNA therefrom. Particularly, the present invention relates to a full-length genomic RNA of JEV represented by SEQ. ID. No 15 and an infectious JEV cDNA therefrom. JEV genomic RNA and infectious JEV ... 10/19/06 - 20060234964 - Inducible plasmid vector encoding tgf-beta and use thereof The present invention provides alternatives to traditional drug and surgical treatments for IBD. In particular, the present invention provides compositions and methods for the treatment of autoimmune diseases such as IBD in humans using TGF-β therapy. The compositions of the present invention provide vectors containing TGF-β under the control of ... 10/12/06 - 20060229273 - High affinity oligonucleotide ligands to growth factors Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGFβ, PDGF and hKGF. Included in the invention are specific RNA and ssDNA ligands to TGFβ1 and PDGF identified by the SELEX method. Also included in the invention are specific RNA ligands to hKGF identified by ... 10/12/06 - 20060229272 - Human g-protein coupled receptor, hgprbmy11, and variants thereof The present invention provides novel polynucleotides encoding HGPRBMY11 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding variants of the HGPRBMY11 polypeptide, HGPRBMY11v1 and HGPRBMY11v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing these polypeptides. The invention further relates to diagnostic ... 10/12/06 - 20060229271 - Methods for treating infectious disease exacerbated asthma The invention relates to methods of treating infectious disease exacerbated asthma. In particular, the methods are useful for treating viral exacerbated asthma using CpG oligonucleotides. ... 10/12/06 - 20060229270 - Methods of treating proteinuria by reducing double-stranded dna antibodies The invention provides methods of treating proteinuria in an individual such as human by administering an effective amount of an agent that reduces the level of anti-dsDNA antibodies (such as a dsDNA epitope as in the form of an epitope-presenting carrier or an epitope-presenting valency platform molecule like LJP 394) ... 10/12/06 - 20060229269 - Emergence of a r-type ca²+ channel (cav 2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage The invention relates to methods and products for treatment of a neurological defect such as a subarachnoid hemorrhage or cerebral vasospasm. Specifically, R-type voltage-gated calcium channel inhibitors and related compositions and kits are described. ... 10/12/06 - 20060229268 - Small interference rna (sirna) molecules for modulating superoxide dismutase (sod) The invention pertains to using double stranded ribonucleic acid molecules such as small interfering RNA (siRNA) molecules to target an SOD gene to interfere with gene expression and SOD protein production. Method are disclosed for inhibiting expression of a target protein in a subject with a neurological disorder by introducing ... 10/12/06 - 20060229267 - Methods and compositions for the inhibition of gene expression The present invention relates to methods and compositions for the inhibition of gene expression. In particular, the present invention provides oligonucleotide-based therapeutics for the inhibition of oncogenes involved in cancers. ... 10/12/06 - 20060229266 - Silencing of tgf-beta receptor type ii expression by sirna The present application is directed to siRNA-based silencing of the type II receptor of TGFβ. siRNAs that target this receptor abrogate the receptor protein and transcript, TGFβ-mediated processes such as fibronectin assembly and cell migration also are inhibited and the molecules of the invention are efficacious in reducing the inflammatory ... 10/05/06 - 20060223779 - Method of screening for inhibitors of human fatty acid-coa ligase 4 The present invention provides a method of screening for potential cancer chemotherapeutic and chemopreventive agents which act by modulating the activity of the Fatty Acid-CoA Ligase 4 (FACL4) gene product in humans. This invention also provides methods of administering such agents to treat cancer by inhibiting the activity of the ... 10/05/06 - 20060223778 - Circular nucleic acid vectors, and methods for making and using the same Circular nucleic acid vectors that provide for persistently high levels of protein expression are provided. The circular vectors of the subject invention are characterized by being devoid of expression-silencing bacterial sequences, where in many embodiments the subject vectors include a unidirectional site-specific recombination product hybrid sequence in addition to an ... 10/05/06 - 20060223777 - Highly functional short hairpin rna The present invention provides improved hairpin and fractured hairpin constructs for use in gene silencing through the RNA interference pathway. An exemplary short hairpin polynucleotide for use in gene silencing can include a polynucleotide having from about 42 nucleotides to about 106 nucleotides configured for being processed by Dicer. The ... 10/05/06 - 20060223776 - Microgel particles for the delivery of bioactive materials Novel microgels, microparticles and related polymeric materials capable of delivering bioactive materials to cells for use as vaccines or therapeutic agents. The materials are made using a crosslinker molecule that contains a linkage cleavable under mild acidic conditions. The crosslinker molecule is exemplified by a bisacryloyl acetal crosslinker. The new ... 10/05/06 - 20060223775 - Nucleotide sequence for treating cancer and infection A nucleotide sequence comprising the nucleotide sequence of a virus belonging to the group of autonomous parvoviruses, and at least one effector nucleotide sequence which encodes an effector polypeptide capable of effecting the destruction or the normalization of cancer cells or cells infected by virus, bacteria, or intra-cellular infectious parasites. ... 10/05/06 - 20060223774 - Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof The present invention relates to the discovery, identification and characterization of toxic agents which are lethal to pathogens and methods for targeting such toxic agents to a pathogen or pathogen infected cells in order to treat and/or eradicate the infection. In particular, the present invention relates to toxic agents which ... 10/05/06 - 20060223773 - Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma. ... 10/05/06 - 20060223772 - Vectors comprising guinea pig cmv regulatory elements The invention comprises novel polynucleotides, and related vectors, host cells, methods, and compositions, containing transcriptional enhancers providing very high levels of expression of operably-linked expressible nucleic acid sequences in eukaryotic cells. Advantageously the enhancers may be used in combination with their naturally-associated promoters and/or other genetic elements that increase transcription. ... 10/05/06 - 20060223771 - Nuclear factor kappab inducing factor The present invention is directed to nuclear factor κB (NFκB)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NFκB. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are ... 10/05/06 - 20060223770 - Irna agents targeting vegf The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified. ... 10/05/06 - 20060223769 - Vaccines using nucleic acid-lipid complexes This invention relates to a vaccine and a method for immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated ... 10/05/06 - 20060223768 - Regulation of gene expression The present invention relates to a method of regulating apoptosis. The method comprises the step of introducing into a cell an RNA construct comprising a nucleotide sequence which is homologous to mRNA within said cell. The mRNA within the cell includes genetic information of a gene element involved in the ... 10/05/06 - 20060223767 - Vector for gene therapy and method of quantifying target protein in mammal or cultured cells with the administration of the vector for gene therapy Disclosed is a vector for gene therapy, by which the blood level of a desired protein can be monitored at high sensitivity when a gene therapy is conducted, wherein the label peptide does not have a physiological activity and has no immunogenicity in many mammals. The vector for gene therapy ... 09/28/06 - 20060217342 - Novel oncogene, recombinant protein derived therefrom, and uses thereof The present invention identifies the total nucleotide sequence of a novel oncogene from human, which is directly involved in such a cancerization mechanism as for cervical cancer induced by HPV infection of cervical epithelial cell and the amino acid sequence of an oncogenic protein encoded thereby, and to provide a ... 09/28/06 - 20060217341 - Dna vaccine formulations This invention relates to novel methods and formulations of nucleic acid pharmaceutical products, specifically formulations of nucleic acid vaccine products and nucleic acid gene therapy products. The formulations of the disclosure stabilize the conformation of DNA pharmaceutical products. ... 09/28/06 - 20060217340 - Methods and products for treating hypertension by modulation of trpc3 channel activity The invention relates to methods and products for treatment of hypertension, high blood pressure and vasospasm. Specifically, TRPC3 channel inhibitors and related compositions and kits are described. ... 09/28/06 - 20060217339 - Antisense oligonucleotide modulation of stat3 expression Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and ... 09/28/06 - 20060217338 - Influenza nucleic acids, polypeptides, and uses thereof Codon-optimized nucleic acids encoding influenza polypeptides and uses of the nucleic acids and polypeptides for inducing immune responses are provided herein. ... 09/28/06 - 20060217337 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA ... 09/28/06 - 20060217336 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA ... 09/28/06 - 20060217335 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA ... 09/28/06 - 20060217334 - |